腹腔热灌注联合多西他赛、奥沙利铂静脉化疗治疗晚期卵巢癌疗效观察

Effect observation of hyperthermic intraperitoneal chemotherapy combined intravenous chemotherapy with docetaxel and oxaliplatin in patients with advanced ovarian cancer

目的:探讨肿瘤细胞减灭术(CRS)后腹腔热灌注联合多西他赛、奥沙利铂静脉化疗治疗晚期卵巢癌的临床疗效。方法:取2011年1月至2014年12月在河北医科大学第二医院就诊的晚期卵巢癌患者42例,其中观察组21例(CRS后+腹腔热灌注+多西他赛、奥沙利铂静脉化疗)、紫杉醇+卡铂组21例(CRS后+紫杉醇、卡铂静脉化疗)。比较两组的疗效、肿瘤控制、腹水控制、生活质量、治疗过程中的不良反应及并发症、无进展生存期(PFS)等。结果:观察组与对照组肿瘤控制差异无统计学意义(P>0.05);腹水控制、生活质量、PFS均优于对照组,差异有统计学意义(P<0.05)。不良反应及并发症无明显差异(P>0.05)。结论:在临床上对于晚期卵巢癌患者采取CRS术后腹腔热灌注联合多西他赛、奥沙利铂静脉化疗,对于患者的疗效、肿瘤控制、腹水控制、生活质量、PFS有提高,且不明显增加不良反应及并发症。

Objective：To evaluate the effect of hyperthermic intraperitoneal chemotherapy combined intravenous chemotherapy with oxaliplatin and docetaxel after cytoreductive surgery （CRS） in patients with advanced ovarian cancer.Methods：A total of 42 cases of advanced （stage III^IV） ovarian cancer patients confirmed by clinical diagnosis between Jan.2011 and Dec.2014 were included in the study.The patients were divided into the study group（n=21 cases） and control groups （n=21 cases）.The study group was treated with docetaxel and oxaliplatin venous chemotherapy and hyperthermic intraperitoneal chemotherapy after CRS.While the control group was treated with paclitaxel and carboplatin venous chemotherapy after CRS.Clinical treatment results for curative effects,remission rate of tumor,controlled rate of ascites,quality of life,toxicity and adverse reactions and PFS were compared and analyzed after treatment.Results：The total remission rate of tumor of the study is better than control group,but the difference was not statistically significant （P〉0.05）.The controlled rate of ascites,quality of life and PFS in the study group were all better than patients in the control group （P〈0.05）.The difference of the rate of toxicity and adverse reactions between the study group and the control group was not statistically significant （P〉0.05）.Conclusion：Applying the combination of docetaxel and oxaliplatin venous chemotherapy and hyperthermic intraperitoneal chemotherapy to treat advanced ovarian cancer after CRS can improve the curative effects,remission rate of tumor,controlled rate of ascites,quality of life,PFS and with little toxicity and adverse reactions.